India Chemical Projects Tracker

The subsidiary had spent about Rs 300 crore by the time manufacturing began at Dahej. Products, capacity and end markets have not been disclosed. The plant's effect on group margins depends on what it goes on to make. Read our news story

The plant sits at Grasim's Vilayat chlor alkali unit, which was chosen for its captive chlorine. Phase 1 is 50,000 tonnes against an original plan of close to 100,000 tonnes built in phases, so phase 2 timing is the next thing to watch. Read our news story

Land at Nagpur is already acquired. The company linked the new site to the end of incentives at its Udhampur unit in March 2026 and expects better logistics. Management describes it as a largely automated formulation plant, not a technical synthesis unit.

Two million tonnes of new PE and PP is a big addition to Indian polymer supply, and import prices could come under pressure once these lines run steadily. The refinery began commercial operations on 22 June 2026 after a fire delayed it.

The board approved Rs 250 crore for 2,500 tonnes, while the draft environmental report filed with the Tamil Nadu pollution board lists 6,850 tonnes at Rs 110 crore. Funding is a mix of internal accruals and term loans. Watch the final clearance to see which capacity figure holds.

The board raised the budget from Rs 1,100 crore, approved in October 2024, to Rs 2,285 crore after a change in project scope. SRF cites expected demand for HFOs and value added hydrogen fluoride products, extending its fluorochemicals chain into next generation refrigerants.

The company's compliance report says construction is underway on the first polymerisation train, the VCM reactor area, the chlor alkali unit and the acetylene unit. It expects all units to start commercial operation by 1 October 2027 and says the PVC will serve the domestic market and reduce reliance on imports.

Groundbreaking took place on 28 February 2026 on a 102 acre site planned for zero liquid discharge with marine discharge. The company says it has received Consent to Establish and started work with technical consultants. It has not disclosed products or capacity for the site itself.

The plan doubles fatty alcohol, erucic acid and glycerine capacity and triples specialities, supporting a goal of a US$1 billion global business before 2030. The company also plans to raise renewable energy use to 75 percent.

The company says the Kurnool plant is running at full capacity and demand is outpacing supply. Output from the new line is due in July 2028, with about Rs 100 crore a year of revenue expected at full scale. Until then, extra demand will have to be met by other suppliers. Read our news story

The Rs 20 crore expansion is funded through bank loans and internal accruals. The test now is how fast customer approvals turn trial batches into regular orders. Read our news story

Existing ibuprofen capacity runs at 95 percent utilisation, so this is demand led. The company describes itself as a leading global ibuprofen maker and will fund the Rs 350 crore cost from internal accruals. Read our news story

IOL will make one specialty chemical exclusively for an unnamed global customer that is not a related party. The company expects the deal to add materially to revenue once supplies start. Read our news story

Phase 1 starts with three large scale products, two for pharma and one for agro. Management said in May 2026 that validation batches were done and orders were in hand. With up to 16 blocks possible on the site, suppliers of reactors, utilities and solvents should expect more orders as later blocks come up.

Management links Site 3++ to growth in its material science business, which was 17 percent of sales. Deliveries from the site to Milliken began in April and May 2026, and the company expects the ramp up to continue in FY27.